The AUA acknowledges and thanks the SUO for their support of this educational opportunity.
Target Audience
This course is designed primarily for urologists who concentrate on genitourinary (GU) cancer in private practice and wish to be involved in the total care of the patient. In many cases the pertinent urologist will be part of a large urology practice group.
Course Description/Purpose/Need
Urologic oncology care mandates taking care of the whole patient by exercising both cognitive and technical skills. This tradition is being challenged by a variety of disciplines. Interventional radiology focuses on the procedural in isolation from the necessary global treatment while medical oncology focuses on advanced disease and the delivery of chemotherapy. The Society of Urologic Oncology (SUO) has concluded that knowledge about the organ system, the disease process, the continuity of care and the treatment and post-treatment outcomes, which are essential for optimal patient care and scientific progress, lie in the domain of urology. Urologic oncology care should be multidisciplinary and should include the disciplines of urologic oncology and medical oncology. Ideally someone needs to be a team leader and this should be a urologist who has training and interest in urologic oncology. The SUO has developed a strategy to address this issue which includes beginning a curriculum that provides training for residents and practicing urologists to meet the challenges that exist in the "nonsurgical" treatment of the urologic patient. Accordingly, this course will present the practical aspects of the systemic therapy for the GU cancer patient and also the practical aspects of percutaneous renal mass ablation and prostate ablation technologies.
The AUA acknowledges the Society of Urologic Oncology (SUO) for their assistance with the development of this course and their educational support.
Learning Objectives
Upon completion of this course, participants should be able to:
determine and utilize (when appropriate) the optimal therapy for GU oncology patients who require systemic treatment
evaluate and utilize the optimal interventional ablation therapies (if appropriate) for kidney and prostate tumors
examine practicalities of setting up a systemic therapy and interventional therapy environments in your practice
Scientific Program Schedule
Friday, August 14, 2009
7:30 – 8 a.m.
Continental Breakfast and Registration
8 – 8:05 a.m.
Welcome and Introductions
Paul H. Lange, MD
8:05 – 8:35 a.m.
The Future of Urologic Oncology: SUO's Strategic Plans and Its Clinical Trial Groups
Paul H. Lange, MD
8:35 – 9:05 a.m.
Secondary Hormone and Other Therapies before Cytotoxic Chemotherapy
Paul F. Schellhammer, MD
9:05 – 9:40 a.m.
Therapies for Bone Health in Prostate Cancer: Bisphosphonates and Rank Ligand Inhibitors
Fred Saad, MD, FRCS
9:40 – 10:20 a.m.
The Economics of Systemic Therapy and Image-Guided Procedures
David F. Penson, MD
10:20 – 10:35 a.m.
Break
10:35 – 11:30 a.m.
The Nuts and Bolts of Setting up a Systemic Therapy Organization and Clinical Trials Group in Practice
Fred Saad, MD, FRCS
Paul F. Schellhammer, MD
David F. Penson, MD
11:30 a.m. – 12:30 p.m.
Lunch with the Experts: Roundtable Discussion and Pre-determined Set of Questions and Reports to Audience
Moderator: Robert C. Flanigan, MD
12:30 – 1 p.m.
Reflections about Systemic Therapy Strategies in Large Private Practice Groups
Peter Knapp, MD
1 – 1:25 p.m.
Cytoreductive Surgery in Renal Cell Cancer and the Pros and Cons of Adjuvant and Neoadjuvant Systemic Therapy
Robert C. Flanigan, MD
1:25 – 2 p.m.
Tyrosine Kinase Inhibitors in Kidney Cancer
Anil Kapoor, MD, FRCSC
2 – 2:45 p.m.
Parenteral Cytotoxics in Prostate, Bladder and Testes
Fred Saad, MD, FRCS
2:45 – 3 p.m.
Break
3 – 3:45 p.m.
Roundtable Discussion: Pros and Cons of SUO’s Strategic Plan Regarding the Future of Urologic Oncology
Robert C. Flanigan, MD, Paul H. Lange, MD, Paul F. Schellhammer, MD, Peter Knapp, MD, and Anil Kapoor, MD, FRCSC
3:45 – 4:30 p.m.
Case Presentations and Discussion
Meeting Adjourns
Saturday, August 15, 2009
7:30 – 8 a.m.
Continental Breakfast and Registration
8 – 8:05 a.m.
Introduction
Louis R. Kavoussi, MD
8:05 – 8:55 a.m.
Basics of Image Guidance Therapies
Louis R. Kavoussi, MD
8:55 – 9:45 a.m.
Basics of Tissue Ablation
Lee Richstone, MD
9:45 – 10:10 a.m.
Technique and Results of Renal Ablation
Louis R. Kavoussi, MD
10:10 – 10:25 a.m.
Break
10:25 – 11:05 a.m.
Angiography and Intra-arterial Chemotherapeutic
Ardeshir R. Rastinehad, DO
11:05 – 11:30 a.m.
New Prostate Ablation Therapies
Michael O. Koch, MD
11:30 a.m. – Noon
Reflections about Interventional Therapies in Large Private Practice Groups
Peter Knapp, MD
Noon – 1 p.m.
Lunch with the Experts: Roundtable Discussion and Pre-determined Set of Questions and Reports to Audience
Moderator: Louis R. Kavoussi, MD
1 – 1:45 p.m.
Image-Guided Radiotherapeutics
Lee Richstone, MD
1:45 – 2:30 p.m.
Nuts and Bolts of Setting up an Interventional Environment
Louis R. Kavoussi, MD
2:30 – 3 p.m.
Case Presentations
Meeting Adjourns
Course Director
Paul H. Lange, MD
Professor of Urology
University of Washington (UW)
Director, Institute of Prostate Cancer Research
UW and Fred Hutchinson Cancer Research Center
Seattle, WA
Louis R. Kavoussi, MD
Professor and Chairman
Smith Institute for Urology
Hofstra School of Medicine
North Shore–LIJ Health System
Long Island, NY
Faculty
Robert C. Flanigan, MD
Chair, Department of Urology
Loyola University Medical Center
Department of Urology
Maywood, IL
Anil Kapoor, MD, FRCSC
Associate Professor of Surgery (Urology) McMaster University
Program Director, McMaster Urology Residency Program
Director, Urologic Research Group
McMaster Institute of Urology at St. Joseph’s Healthcare
Chair, GU Oncology Program, Juravinski Cancer Centre
Ontario, Canada
Michael O. Koch, MD
Professor and Chair
Indiana University School of Medicine
Department of Urology
Indianapolis, IN
Peter M. Knapp, MD
Urology of Indiana
Clinical Associate Professor of Urology
Indiana University School of Medicine
Indianapolis, IN
David F. Penson, MD
Associate Professor of Urology and Preventive Medicine
USC/Norris Cancer Center
Department of Urology
Los Angeles, CA
Ardeshir R. Rastinehad, DO
Urologic Oncology Fellow
National Cancer Institute, National Institutes of Health
Urologic Oncology Branch
Center for Cancer Research
Bethesda, MD
Lee Richstone, MD
Director of Laparoscopy and Robotic Surgery
Associate Program Director
The Smith Institute for Urology
New Hyde Park, NY
Assistant Professor of Urology
Albert Einstein College of Medicine
New York, NY
Paul F. Schellhammer, MD
Professor of Urology
Eastern Virginia Medical School
Norfolk, VA
Fred Saad, MD, FRCS
Professor and Chair
Division of Urology
University of Montreal Endowed Chair in Prostate Cancer
Director of Urologic Oncology
University of Montreal
Montreal, Quebec
Canada
Hotel and Transportation Information
The Fairmont hotel is at once traditional and contemporary. Just a short distance from the lake and near the renowned shopping of the Magnificent Mile, its sleek tower rests on the edge of leafy Grant and Millennium parks. The interiors are refined, with rich colors and antique reproductions, and spectacular lakefront views define many of the elegant accommodations. Diners and critics alike are singing the praises of the American dishes at Aria restaurant, and afternoon tea is a special event at the Lobby Lounge.
Telephone:
312-565-8000
To hold a reservation, a major credit card number must be provided.
Guest Room Rate:
$179 single/double occupancy. Reference the AUA Global Genitourinary Oncology to receive the special group rate. Once the AUA group block is full, which may be prior to the cut-off date, the AUA is unable to guarantee rooms at this rate or this hotel.
Cut-off Date:
Sunday, July 19, 2009
Guest rooms may not be available at the AUA special rate after this date.
Cab fare from Midway Airport is approximately $35 and takes approximately 30 minutes travel time. Cab fare from O’Hare Airport $45 and takes approximately 15-30 minutes travel time. Travel time is dependent on time of day and traffic conditions.
Car Rental:
Avis is offering special discounted rates to all meeting attendees. Reservations can be made by calling 1-800-331-1600; reference the AUA Avis World Wide Discount (AWD) number J907607 or visit www.avis.com. Be sure to enter the AWD number J907607 and "Best" in the rate code to receive the available discount.
Registration Fees and Information
AUA Member
$600
Non-member
$725
Cancellation Policy
Through June 19, 2009 the cancellation fee is $75. If you cancel between June 19, 2009 and July 17, 2009, the cancellation fee is $125. There are no refunds after July 17, 2009. The AUA has the right to cancel this course if a minimum enrollment is not reached by Monday, July 13, 2009. If the AUA cancels this course registration fees will be refunded in full and notification will be sent by Wednesday, July 15, 2009.
Conference Confirmation
A written confirmation will be sent from our office approximately two weeks after your registration is received and processed.
Accreditation
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
The AUA takes responsibility for the content, quality and scientific integrity of this CME activity.
Credit Designation
The AUA designates this educational activity for a maximum of 13.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AUA Disclosure Policy
As a provider accredited by the ACCME, the AUA must ensure balance, independence, objectivity and scientific rigor in all its activities.
All faculty participating in an educational activity provided by the AUA are required to disclose to the audience any relevant financial relationships with any commercial interest to the provider. The intent of this disclosure is not to prevent faculty with relevant financial relationships from serving as faculty, but rather to provide members of the audience with information on which they can make their own judgments. The AUA must resolve any conflicts of interest prior to the commencement of the educational activity. It remains for the audience to determine if the faculty’s relationships may influence the educational content with regard to exposition or conclusion. When unlabeled or unapproved uses of drugs or devices are discussed, these are also indicated.
Unlabeled or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to unlabeled or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this CME activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Evidence-based Content
As a provider of CME accredited by the ACCME, it is the policy of the AUA to review and certify that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias.
Audio, Video and Photographic Equipment
Audio, video and other photographic recording equipment is prohibited inside AUA meeting rooms.
Special Assistance
The AUA, an organization accredited for CME, complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 800-908-9414.
back to top